In spite of intensive research, glioblastoma remains one of the most lethal types of brain cancer. Temozolomide (TMZ) is used ...

In these drug-resistant cancer cells, DNA becomes mutated but does not lead to cell death. The researchers at the Center for ...

New research shows that glioblastoma has an internal clock and syncs its daily rhythms to match -- and take advantage of -- the rhythms of its host. In this way, brain tumors grow in response to the ...

Blinatumomab plus chemotherapy represents a new standard of care for most children with NCI standard-risk B-cell ALL, according to Rachel E. Rau, MD.

The drug has demonstrated an impressive ability to slow tumor growth in animals by 82% while selectively targeting cancer cells far more effectively than traditional chemotherapy agents.

Disease-free survival (DFS) rates at 3 years were significantly improved with the addition of blinatumomab (Blincyto) to risk ...

Meta: Blinatumomab plus chemotherapy, vs chemotherapy alone, significantly improved DFS rates and was well tolerated in ...

SAN DIEGO -- Children with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) lived significantly longer without ...

The Netherlands Cancer Institute has found that the estrous cycle stage significantly influences mammary tumors' sensitivity ...

No encephalopathy was reported during the second cycle of Blincyto. In the standard risk-average population, higher rates of ...

Even newer features are being developed such as using targeted drugs as the payload instead of chemotherapy, such as small ...

Try Breyanzi ® (lisocabtagene maraleucel), a one-time infusion* used to treat adults with relapsed or refractory large B cell ...